Pathologic complete response achieved with tislelizumab, cetuximab, and dabrafenib in BRAF V600E-mutant metastatic colorectal cancer

▸ TREATMENT

A case report describes a 26-year-old woman with microsatellite-stable, BRAF V600E-mutant stage IVC disease who achieved complete remission with first-line immunotherapy and targeted therapy combination, without cytotoxic chemotherapy. (Anticancer Drugs)